Symptomatic therapy in multiple sclerosis

Teresa C. Frohman; Wanda Castro; Anjali Shah; Jeffrey L Ortstadt; Jeffrey Ortstadt; Scott L. Davis; Diana Logan; Thomas Abraham; Jaspreet Abraham; Gina Remington; Katherine Treadaway; Benjamin Greenberg; Anjali Shah; John Hart; Olaf Stuve; Gary E Lemack; Elliot Frohman

doi:10.1177/1756285611400658

Symptomatic therapy in multiple sclerosis

Teresa C. Frohman, Wanda Castro, Anjali Shah, Jeffrey L Ortstadt, Jeffrey Ortstadt, Scott L. Davis, Diana Logan, Thomas Abraham, Jaspreet Abraham, Gina Remington, Katherine Treadaway, Benjamin Greenberg, Anjali Shah, John Hart, Olaf Stuve, Gary E Lemack, Elliot Frohman

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Multiple sclerosis is the most common disabling neurological disease of young adults. The ability to impact the quality of life of patients with multiple sclerosis should not only incorporate therapies that are disease modifying, but should also include a course of action for the global multidisciplinary management focused on quality of life and functional capabilities.

Original language	English (US)
Pages (from-to)	83-98
Number of pages	16
Journal	Therapeutic Advances in Neurological Disorders
Volume	4
Issue number	2
DOIs	https://doi.org/10.1177/1756285611400658
State	Published - Mar 2011

Keywords

fatigue
multiple sclerosis
neurogenic bowel and bladder
spasticity
symptomatic therapy
visual symptoms

ASJC Scopus subject areas

Pharmacology
Neurology
Clinical Neurology

Access to Document

10.1177/1756285611400658

Cite this

Frohman, T. C., Castro, W., Shah, A., Ortstadt, J. L., Ortstadt, J., Davis, S. L., Logan, D., Abraham, T., Abraham, J., Remington, G., Treadaway, K., Greenberg, B., Shah, A., Hart, J., Stuve, O., Lemack, G. E., & Frohman, E. (2011). Symptomatic therapy in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 4(2), 83-98. https://doi.org/10.1177/1756285611400658

@article{354dcb7ca37945c9b767342dc70720cd,

title = "Symptomatic therapy in multiple sclerosis",

abstract = "Multiple sclerosis is the most common disabling neurological disease of young adults. The ability to impact the quality of life of patients with multiple sclerosis should not only incorporate therapies that are disease modifying, but should also include a course of action for the global multidisciplinary management focused on quality of life and functional capabilities.",

keywords = "fatigue, multiple sclerosis, neurogenic bowel and bladder, spasticity, symptomatic therapy, visual symptoms",

author = "Frohman, {Teresa C.} and Wanda Castro and Anjali Shah and Ortstadt, {Jeffrey L} and Jeffrey Ortstadt and Davis, {Scott L.} and Diana Logan and Thomas Abraham and Jaspreet Abraham and Gina Remington and Katherine Treadaway and Benjamin Greenberg and Anjali Shah and John Hart and Olaf Stuve and Lemack, {Gary E} and Elliot Frohman",

year = "2011",

month = mar,

doi = "10.1177/1756285611400658",

language = "English (US)",

volume = "4",

pages = "83--98",

journal = "Therapeutic Advances in Neurological Disorders",

issn = "1756-2856",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Symptomatic therapy in multiple sclerosis

AU - Frohman, Teresa C.

AU - Castro, Wanda

AU - Shah, Anjali

AU - Ortstadt, Jeffrey L

AU - Ortstadt, Jeffrey

AU - Davis, Scott L.

AU - Logan, Diana

AU - Abraham, Thomas

AU - Abraham, Jaspreet

AU - Remington, Gina

AU - Treadaway, Katherine

AU - Greenberg, Benjamin

AU - Shah, Anjali

AU - Hart, John

AU - Stuve, Olaf

AU - Lemack, Gary E

AU - Frohman, Elliot

PY - 2011/3

Y1 - 2011/3

N2 - Multiple sclerosis is the most common disabling neurological disease of young adults. The ability to impact the quality of life of patients with multiple sclerosis should not only incorporate therapies that are disease modifying, but should also include a course of action for the global multidisciplinary management focused on quality of life and functional capabilities.

AB - Multiple sclerosis is the most common disabling neurological disease of young adults. The ability to impact the quality of life of patients with multiple sclerosis should not only incorporate therapies that are disease modifying, but should also include a course of action for the global multidisciplinary management focused on quality of life and functional capabilities.

KW - fatigue

KW - multiple sclerosis

KW - neurogenic bowel and bladder

KW - spasticity

KW - symptomatic therapy

KW - visual symptoms

UR - http://www.scopus.com/inward/record.url?scp=79955990115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955990115&partnerID=8YFLogxK

U2 - 10.1177/1756285611400658

DO - 10.1177/1756285611400658

M3 - Review article

C2 - 21694806

AN - SCOPUS:79955990115

SN - 1756-2856

VL - 4

SP - 83

EP - 98

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

IS - 2

ER -

Symptomatic therapy in multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this